Hogan Lovells advises Eli Lilly and Company on the conclusion of a framework agreement with the EU Commission for COVID-19 treatment

The framework agreement covers the supply of up to 220,000 doses of a combination therapy of two monoclonal antibodies for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. 

The combination therapy consisting of the two antibodies is currently under review by the European Medicines Agency (EMA). Treatment of patients will only take place after the therapy has been approved for emergency use at the national level or approved at the EU level. 

Hogan Lovells previously advised Eli Lilly and Company on a supply agreement with the German Federal Ministry of Health (BMG) for antibody therapy supply for the treatment of Covid-19. 

Eli Lilly Team (Legal)

The contracts were handled by a cross-functional international team led by Oliver Stahl (Senior Director Corporate Affairs), with legal support provided by Nicole Könecke (Director Legal - supply contract with BMG) and Dr. Thomas Jochheim (Senior Legal Counsel - tender and framework agreement with the EU Commission).

Hogan Lovells team for Eli Lilly

Arne Thiermann (Partner, Strategic Operations, Agreements and Regulation (SOAR) - Life Sciences, Hamburg), Ciara Kennedy-Loest (Partner, Competition, Public & EU Law, London), Fabien Roy (Partner, Medical Device and Technology, Brussels), Dr. Benjamin Göhl (Associate, Strategic Operations, Agreements and Regulation (SOAR) - Life Sciences, Munich), Katharina Kranzfelder (Senior Associate, Business Restructuring and Insolvency, Munich).